CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
IPFA welcomes Marion Lanteri as Executive Board member, CTS as new member organization
As winter weather continues to move through parts of the US, we would like to remind you it may be n...
Reminder - Dr. Buff Mair is the new CTS Medical Director. Several of the CTS client forms specify li...
On September 14, 2020, our Phoenix laboratory began performing a portion of our alternate donor anti...
CTS will be transitioning to a new sFTP server for clients who send test request and/or receive...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...